Sun Pharma Advanced Research Company
SPARCNSE

Sun Pharma Advanced Research Company

₹131.4519.56 (17.48%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
112.55
Today’s high
133.70
52 week low
108.00
52 week high
204.40
Open price
112.89
Previous close
111.89
Live volume
1,38,40,637
Lower circuit
105.16
Upper circuit
157.74

Fundamentals

Market Cap
₹4,276Cr
ROE
77.47%
P/E Ratio(TTM)
-15.95
EPS(TTM)
-8.26
P/B Ratio
0.00
Dividend Yield
0.00%
Industry P/E
31.48
Book Value
-10.62
Debt to Equity
-1.21
Face Value
1

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About

Sun Pharma Advanced Research Company (SPARC) is a clinical-stage bio-pharmaceutical company focusing on research and development of innovative therapeutics.;
MD/CEO
Anilkumar Raghavan
Founded in
2006
NSE symbol
SPARC
Industry

Shareholding Pattern

Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Promoters
65.67%
Retail And Others
31.51%
Foreign Institutions
2.04%
Mutual Funds
0.76%
Other Domestic Institutions
0.03%

Mutual Funds Invested (1)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹711.55
+20.55 (2.97%)
L
    H
    4,080.1430.814
    ₹404.55
    +9.40 (2.38%)
    L
      H
      3,779.3342.175.18
      Aarti DrugsAARTIDRUGS
      ₹341.10
      +5.65 (1.68%)
      L
        H
        3,110.0315.362.12
        ₹268.15
        +3.80 (1.44%)
        L
          H
          2,927.3561.211.07
          Livesquawk
          SPARC posts Q3 net loss of 806M rupees vs 797M YoY. Revenue declines to 85M rupees from 149M YoY.
          Livesquawk
          Sun Pharma Advanced Research got USFDA's Rare Pediatric Disease Priority Review Voucher. The voucher follows the approval of its drug Sezaby by the USFDA.
          Livesquawk
          SPARC to issue convertible warrants worth up to ₹6B at ₹155.8 each.
          2026
          9
          Feb
          Quarterly Result
          Release date
          2025
          10
          Nov
          Quarterly Result
          Release date
          4
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks